Historically, the management of lymph node positive prostate cancer was limited to androgen deprivation therapy, but increasing data now support the use of multimodality therapy. As treatment options have expanded, patient-centered decision making has become increasingly complicated.

When implementing newer technologies practices often rely on vendor training, an evaluation of published literature, and collaboration with others experienced in the technology. Incident learning has a critical role in radiation therapy and may be most important in new and emerging technologies.

The use of SABR is well established in many cancers, however, its application within kidney cancer is relatively new. This is largely due to the historical notion that renal cell carcinoma (RCC) is highly radioresistant.

Bone sarcomas are routinely diagnosed in the adolescent and young adult population.